Cinnamon extract suppresses experimental colitis through modulation of antigen-presenting cells

AIM:To investigate the anti-inflammatory effects of cinnamon extract and elucidate its mechanisms for targeting the function of antigen presenting cells.METHODS:Cinnamon extract was used to treat murine macrophage cell line(Raw 264.7),mouse primary antigen-presenting cells(APCs,MHCII+) and CD11c+dendritic cells to analyze the effects of cinnamon extract on APC function.The mechanisms of action of cinnamon extract on APCs were investigated by analyzing cytokine production,and expression of MHC antigens and co-stimulatory molecules by quantitative real-time PCR and flow cytometry.In addition,the effect of cinnamon extract on antigen presentation capacity and APC-dependent T-cell differentiation were analyzed by [H3]-thymidine incorporation and cytokine analysis,respectively.To confirm the anti-inflammatory effects of cinnamon extract in vivo,cinnamon or PBS was orally administered to mice for 20 d followed by induction of experimental colitis with 2,4,6 trinitrobenzenesulfonic acid.The protective effects of cinnamon extract against experimental colitis were measured by checking clinical symptoms,histological analysis and cytokine expression prof iles in inflamed tissue.RESULTS:Treatment with cinnamon extract inhibited maturation of MHCII+ APCs or CD11c+ dendritic cells(DCs) by suppressing expression of co-stimulatory molecules(B7.1,B7.2,ICOS-L),MHCII and cyclooxygenase(COX)-2.Cinnamon extract induced regulatory DCs(rDCs) that produce low levels of pro-inflammatory cytokines [interleukin(IL)-1β,IL-6,IL-12,interferon(IFN)-γ and tumor necrosis factor(TNF)-α] while expressing high levels of immunoregulatory cytokines(IL-10 and transforming growth factor-β).In addition,rDCs generated by cinnamon extract inhibited APC-dependent T-cell proliferation,and converted CD4+ T cells into IL-10high CD4+ T cells.Furthermore,oral administration of cinnamon extract inhibited development and progression of intestinal colitis by inhibiting expression of COX-2 and pro-inflammatory cytokines(IL-1β,IFN-γ and TNF-α),while enhancing IL-10 levels.CONCLUSION:Our study suggests the potential of cinnamon extract as an anti-inflammatory agent by targeting the generation of regulatory APCs and IL-10+ regulatory T cells.

Activation of killer cells with soluble gastric cancer antigen combined with anti-CD3 McAb

ＩＮＴＲＯＤＵＣＴＩＯＮＴｈｅｒｅｈａｖｅｂｅｅｎｍａｎｙｒｅｐｏｒｔｓｏｎｃａｎｃｅｒｔｈｅｒａｐｙｗｉｔｈｌｙｍｐｈｏｋｉｎｅａｃｔｉｖａｔｅｄｋｉｌｅｒ（ＬＡＫ）ｃｅｌｓａｎｄｉｎｔｅｒｌｅｕｋｉｎ２（ＩＬ２），ｂｕｔｔｈｅｐｒｏｌｉｆｅ...

The human leucocyte differentiation antigens (HLDA) workshops: the evolv-ing role of antibodies in research, diagnosis and therapy

The 8^th International Workshop on Human Leucocyte Differentiation Antigens （chaired by HZ and managed by BS） was run over a 4-year period and culminated in a conference in December 2004. Here we review the achievements of the HLDA Workshops and provide links to information on CD molecules and antibodies against them, including the 93 new CDs assigned in the 8^th Workshop. We consider what remains to be achieved （including an estimate of the number of leucocyte surface molecules still to be discovered）, and how the field can best move forward.

Impact of PRRSV on activation and viability of antigen presenting cells

Porcine reproductive and respiratory syndrome(PRRS) is one of the most important diseases of swine industry. The causal agent, PRRS-virus(PRRSV), is able to evade the host immune response and survive in the organism causing transient infections. Despite all scientific efforts, there are still some gaps in the knowledge of the pathogenesis of this disease. Antigen presenting cells(APCs), as initiators of the immune response, are located in the first line of defense against microorganisms, and are responsible for antigen recognition, processing and presentation. Dendritic cells(DCs) are the main type of APC involved in antigen presentation and they are susceptible to PRRSV infection. Thus, PRRSV replication in DCs may trigger off different mechanisms to impair the onset of a host effective immune response against the virus. On the one side, PRRSV may impair the basic functions of DCs by regulating the expression of major histocompatibility complex class Ⅱ and CD80/86. Other strategy followed by the virus is the induction of cell death of APCs by apoptosis, necrosis or both of them. The impairment and/or cell death ofAPCs could lead to a failure in the onset of an efficient immune response, as long as cells could not properly activate T cells. Future aspects to take into account are also discussed in this review.

Key role of human leukocyte antigen in modulating human immunodeficiency virus progression: An overview of the possible applications

Host and viral factors deeply influence the human immunodeficiency virus(HIV) disease progression. Among them human leukocyte antigen(HLA) locus plays a key role at different levels. In fact, genes of the HLA locus have shown the peculiar capability to modulate both innate and adaptive immune responses. In particular, HLA class Ⅰmolecules are recognized by CD8+ T-cells and natural killers(NK) cells towards the interaction with T cell receptor(TCR) and Killer Immunoglobulin Receptor(KIR) 3DL1 respectively. Polymorphisms within the different HLA alleles generate structural changes in HLA classⅠpeptide-binding pockets. Amino acid changes in the peptide-binding pocket lead to the presentation of a different set of peptides to T and NK cells. This review summarizes the role of HLA in HIV progression toward acquired immunodeficiency disease syndrome and its receptors. Recently, many studies have been focused on determining the HLA binding-peptides. The novel use of immune-informatics tools, from the prediction of the HLA-bound peptides to the modification of the HLAreceptor complexes, is considered. A better knowledge of HLA peptide presentation and recognition are allowing new strategies for immune response manipulation to be applied against HIV virus.

Studies on mechanism of Sialy Lewis-X antigen in liver metastases of human colorectal carcinoma

INTRODUCTIONSialyl Lewis-X antigen ,correlated with carcinoma, is a group of carbohydrate antigen containing oligosaccharide expressed of embryonic tisue and glycoproteins on cell surface of embryonic tissue[1].The SLeX antigen located on cell surface is synthesized principally by two enzymes ,al ,3fucosyltransfrease and a2, 3sialyctransferase.In adults ,SLeX antigen is expressed principally on the surfaces of granulocytic cells and some tumor cells .

The Secondary Structure of Heated Whey Protein andIts Hydrolysates Antigenicity

Fourier transform infrared spectroscopy(FTIR) and circular dichroism(CD) were used to investigate the conformational changes of heated whey protein(WP) and the corresponding changes in the hydrolysates immunoreactivity were determined by competitive enzyme-linked immunosorbent assay(ELISA).Results showed that the contents of α-helix and β-sheet of WP did not decrease much under mild heating conditions and the antigenicity was relatively high;when the heating intensity increased(70 ℃ for 25 min or 75 ℃ for 20 min),the content of α-helix and β-sheet decreased to the minimum,so was the antigenicity;However,when the WP was heated at even higher temperature and for a longer time,the β-sheet associated with protein aggregation begun to increase and the antigenicity increased correspondingly.It was concluded that the conformations of heated WP and the antigenicity of its hydrolysates are related and the optimum structure for decreasing the hydrolysates antigeniity is the least content of α-helix and β-sheet.Establishing the relationship between the WP secondary structure and WP hydrolysates antigenicity is significant to supply the reference for antigenicity reduction by enzymolysis.

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Aim:Anti-CD20 monoclonal antibody is a cornerstone therapy for follicular lymphoma.Following anti-CD20 therapy,a potential decrease in CD20 antigen,and therefore a loss of the tumor target might be expected.However,the incidence and clinical significance of CD20 loss on tumor cells in patients with relapsed or refractory follicular lymphoma are unknown.This study aims to investigate the incidence and outcome of patients with relapsed or refractory follicular lymphoma patients harboring the loss of the tumor target,CD20.Methods:All consecutive adult patients with relapsed or refractory follicular lymphoma referred to the Early Drug Department at Gustave Roussy were included.The main objectives were to assess the incidence and prognosis of the loss in expression of CD20 antigen on the surface of tumor cells on patient outcome.Results:Over the study period 2013-2018,131 patients were screened for clinical trials with B-cell malignancies in the early drug department of Gustave Roussy in France.Forty-four patients presented with relapsed or refractory follicular lymphoma and 32 had tumor biopsies at the time of relapse that were retained for analysis.The median(range)age was 67.5 years(55.3-75.3)and the median number of prior anti-cancer systemic therapies was 3(2-4).At the time of relapse,CD20 expression was positive in 84%of tumors(n=27)and negative in 16%of tumors(n=5).At a median follow-up of 18.3(0.6-83.3)months,CD20 negativity was associated with a poorer prognosis with a median overall survival of 8.9 months(95%CI:2.4-19.1)in comparison to CD20 positive patients(28.3 months,95%CI:25.1-75.3 months,P=0.019).Conclusion:The loss of the tumor target antigen,CD20,occurred in 16%of patients with relapse or refractory follicular lymphoma.Due to confounding factors in patients who received anti-CD20 immunotherapy,it was not possible to formally establish the prognostic significance of CD20 negativity.However,we suggest that a check for CD20 antigen positivity nevertheless be performed to adapt subsequent therapies for patients with relapsed or refractory follicular lymphoma.

Detection of microbial antigenic components of circulating immune complexes in HIV patients:Involvement in CD4^+ T lymphocyte count depletion

Objective:To investigate the prevalence of microbial antigenic components of circulating immune complexes amongst grades of CD4 T lymphocyte counts in HIV sero positive and seronegative participants.Methods:Polyethelene glycol(PEG-600) and buffering methods of precipitation and dissociation of immune complexes was used to generate immune solution from sera of 100 HIV sero-positive and 100 HIV sero-negative participants.These were categorized into 3 grades based on CD4 count:】 500 cell/mm,200-499 cell/mm3 and 【200 cell/mm3.The immune solutions were assayed using membrane based immunoassay and antibody titration, along side its unprocessed serum for detection of various microbial antigens and or antibodies. CD4 T cell counts were estimated using Patec Cyflow SL-3 Germany.Results:Antigenic component of immune complexes of various infectious agents was detected in 99 and 70 HIV seropositive and HIV sero-negative participants,respectively.In group A,there were 10 HIV positive participants,including 4(40.0%) had circulating immune complexes(CICs) due to Salmonella species only:1(10.0%) due to Salmonella-Plasmodium falciparum(P.falciparum),SalmonellaP. falciparum-HCV and P.falciparum antigens,respectively.In group B,45(45.4%) HIV seropositive participants with CICs had CD4 T lymphocyte count between 200-499 cells/mm^3.Out of these,20(44.4%) had CICs due to Salmonella species only:9(20%) due to Salmonella-P. falciparum.In group C,there were 44(44.4%) HIV sero-positive participants,including 3(6.8%) due to Salmonella species only:24(54.4%) due to Salmonella-P.falciparum:2(4.5%) due to P. falciparum only.Conclusions:In HIV sero-positive participants,presence of heterogeneity of Salmonella species-P.falciparum antigens was highly incriminated in CD4 count depletion but not homogeneity of malaria parasites antigens.Malaria parasites antigens only were incriminated in CD4^+ count depletion amongst HIV sero-negative participants.Before taking any decision on the management of HIV-1-positive individuals,their malaria and Salmonella paratyphi status should be assessed,but not malaria status alone.

EXPRESSION CLONING OF A PROTECTIVE LEISHMANIA ANTIGEN

Parasite-specific CD8+ T cells have been shown to transfer protection against nLeishmania major in susceptible BALB/c mice.An epitope-tagged expression library was used to identify the antigen recognized by a protective CD8+ T cells clone. The expression library allowed recombinant proteins made in bacteria to be captured by macrophages for presentation to T cells restricted to major histompatibility complex class n. A conserved 36-kilodalton member of the tryptophanaspartic acid repeat family of proteins was identified that was expressed in both stages of the parasite life cycle. A 24-kilodalton portion of this antigen protected susceptible mice when administered as a vaccine with interleukin-12before injection.

Rejection of Experimental Hodgkins Lymphoma by T-Cells Engineered with a CD19 Chimeric Antigen Receptor

T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) signaling domain for triggering cell activation are being used for immunotherapeutic targeting of tumor cells in a non-HLA restricted manner. In this study we transduced T cells with a CD19-CAR construct containing a truncated CD34 gene (tCD34) marker and used these to target the B cell antigen CD19 on the surface of a Hodgkin’s lymphoma (HL) cell line (L591) both in vitro and in vivo. Levels of tCD34 expression in transduced peripheral blood mononuclear cells (PBMCs) ranged from 6% - 20% and this was increased to 82% after selection for transduced tCD34+ cells. In vitro cytotoxicity testing on a CD19+ HL cell line (L591) showed specific cell lysis initiated by the CD19-CAR transduced PBMCs. Importantly, CD19-CAR T cells prevented the growth of L591 HL tumor cells when co-injected subcutaneously (sc) in 6/6 severe combined immunodeficient (SCID) mice. There was no evidence of anti-tumor activity when CD19-CAR T cells were infused intravenously (iv) at the same time as L591 HL tumor cells were injected sc. However, 3/6 SCID mice showed tumor rejection within 83 days after iv infusion of CD19-CAR T cells 3 - 9 days after establishment of L591 HL tumors, while all control animals succumbed to tumors within 60 days. Interestingly, immuno-histochemical analysis of L591 HL tumors demonstrated that CD19-CAR T cells were detected not earlier than 11 days after infusion within the tumor mass. These results suggest that CD19 is a potentially attractive target for the immunotherapy of HL.

Regulatory T cells suppress autoreactive CD4^+ T cell response to bladder epithelial antigen

AIM： To investigate the role of regulatory T （Treg） cells in CD4^＋ T cell-mediated bladder autoimmune infammation. METHODS： Urothelium-ovalbumin （URO-OVA）/OT-II mice, a double transgenic line that expresses the membrane form of the model antigen （Ag） OVA as a self-Ag on the urothelium and the OVA-specific CD4^＋ T cell receptor specifc for the I-Ab/OVA323-339 epitope in the periphery, were developed to provide an autoimmune environment for investigation of the role of Treg cells in bladder autoimmune infammation. To facilitate Treg cell analysis, we further developed URO-OVA^GFP-Foxp3/OT-II mice, a derived line of URO-OVA/OT-II mice that express the green fuorescent protein （GFP）-forkhead box protein P3 （Foxp3） fusion protein. RESULTS： URO-OVA/OT-II mice failed to develop bladder infammation despite the presence of autoreactive CD4^＋ T cells. By monitoring GFP-positive cells, bladder infltration of CD4^＋ Treg cells was observed in URO-OVA^GFP-Foxp3/OT-II mice. The infiltrating Treg cells were functionally active and expressed Treg cell effector molecule as well as marker mRNAs including transforming growth factor-β, interleukin （IL）-10, fibrinogen-like protein 2, and glucocorticoid-induced tumor necrosis factor receptor （GITR）. Studies further revealed that Treg cells from URO-OVA^GFP-Foxp3/OT-II mice were suppressive and inhibited autoreactive CD4^＋ T cell proliferation and interferon （IFN）-g production in response to OVA Ag stimulation. Depletion of GITR-positive cells led to spontaneous development of bladder infammation and expression of inflammatory factor mRNAs for IFN-γ, IL-6, tumor necrosis factor-α and nerve growth factor in URO-OVA^GFP-Foxp3/OT-II mice. CONCLUSION： Treg cells specifc for bladder epithelial Ag play an important role in immunological homeostasis and the control of CD4^＋ T cell-mediated bladder autoimmune infammation.

Role of CD20^+ T cells in multiple sclerosis:implications for treatment with ocrelizumab

Features of CD20^+T cells:CD20 is a membrane-spanning hosphoprotein strongly expressed on the cell surface of B lineage cells and is widely regarded as a B cell specific marker.However,CD20(Figure 1)is also expressed at a low level on a small subset of CD3^+T cells which therefore are sometimes referred to as CD20dimCD3^+T cells in contrast to CD20brightCD19^+B cells which represent the majority of cells expressing CD20(Hultin et al.,1993).The amount of the CD20 antigen has been assessed to be 25 to 50 times higher on CD20^+CD19^+B cells compared to CD20^+CD3^+T cells(Hultin et al.,1993).At first description of this cell population the frequency of these CD20^+T cells has been described to represent an average of 2.4%of all peripheral blood lymphocytes(50 healthy controls)(Hultin et al.,1993).

Loss of CD20 expression in relapsed diffuse large B cell lymphoma after rituximab therapy:a case report and review of the literature

Nowadays, resistance to rituximab has become a major issue in clinical practice. And loss of CD20 may contribute to it. Here we presented a case of loss of CD20 expression in relapsed diffuse large B cell lymphoma treated with rituximab and discuss the incidence, mechanism, influence factors, specific markers, prognosis and treatment of this disease. These results suggested that a post-relapse biopsy after rituximab treatment shguld be performed. CD79a and Pax-5 should be used as the first-line B lineage-specific markers for these patients. Though mechanisms of CD20 decrement are not fully elucidated, the down-regulation of CD20 mRNA is the most probable hypothesis. Recently various new agents are developed, but the prognosis is still poor. Further studies for new treatments are needed.

Sustained Remission with Mogamulizumab in Peripheral T Cell Lymphoma with Aberrant CD20 Expression: Case Report and Literature Review

A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.

异常表达CD20的结外NK/T细胞淋巴瘤病理特点分析并文献复习

目的探索异常表达CD20的结外NK/T细胞淋巴瘤的病理形态特点、诊断要点及鉴别诊断。方法分析3例异常表达CD20的结外NK/T细胞淋巴瘤,结合病理形态特点、免疫表型及与其他形态学特点和免疫表型类似的淋巴瘤的鉴别诊断,并进行文献复习。结果异常表达CD20的结外NK/T细胞淋巴瘤形态学特点与普通型结外NK/T细胞淋巴瘤类似,免疫表型表现为部分T细胞标记阳性、CD56、细胞毒标记物、EBER ISH阳性、CD20弱-中等阳性,其余B细胞标记物CD79a、PAX-5均为阴性。其中2例肿瘤细胞阳性表达CD8。结论异常表达CD20的结外NK/T细胞淋巴瘤是一种罕见免疫表型的NK细胞源性淋巴瘤,需要综合分析抗体表达情况及和其他淋巴瘤进行鉴别诊断,免疫组织化学染色阳性模式以及多抗体联合应用对于明确诊断有重要作用。

韦氏环伴滤泡辅助T细胞表型并异常表达CD20的外周T细胞淋巴瘤1例并文献复习

目的探讨韦氏环伴滤泡辅助T细胞表型的外周T细胞淋巴瘤(Waldeyer’s ring peripheral T-cell lymphoma with T-follicular helper phenotype,wPTCL-TFH)临床病理学、遗传学特征及预后。方法收集1例wPTCL-TFH临床资料,对其病变组织行HE、免疫组化染色、EBER原位杂交及TCR基因重排检测,应用一代测序法检测IDH2 Exon4基因突变情况,并复习相关文献。结果患者女性,61岁,临床表现为咽痛、消瘦,无其他发热、盗汗等B症状。组织学表现为扁桃体实质内小-中等大淋巴细胞弥漫浸润。免疫表型:肿瘤细胞表达全T细胞标志物及滤泡辅助T细胞标志物:CD10、BCL6和PD-1,弥漫表达CD20,部分表达CD30(约10%);TCR基因单克隆性重排,IDH2基因未见突变。采用R-CHOP方案化疗6个周期,随访7个月,患者无瘤生存。结论wPTCL-TFH异常表达CD20者临床罕见,化疗中加入利妥昔单抗可能对CD20异常表达wPTCL-TFH有效,仍需更多的病例进一步证实。

抗CD3/CD20双特异性抗体生物学活性测定方法的建立

目的建立基于报告基因的抗CD3/CD20双特异性抗体生物学活性检测方法。方法以WIL2-S细胞系作为靶细胞,以Jurkat-NF-κB-Luc转基因细胞系作为效应细胞,对抗体的量效范围、孵育时间、诱导时间、效靶比及细胞接种密度进行优化,构建可用于测定抗CD3/CD20双特异性抗体生物学活性的报告基因法。依据ICHQ2的指导原则对方法进行全面验证,包括专属性、准确性、精密度、线性、稳定性。结果成功建立了具有量效关系的抗CD3/CD20双特异性抗体生物学活性检测方法,该方法的抗体起始浓度为500 ng/mL,稀释倍数为1∶4,共计8个浓度点(500,125,31.25,7.81,1.95,0.49,0.12,0.031 ng/mL),效靶比为4∶1,诱导时间为4 h。本方法具有良好的专属性;5个不同稀释组回收率样品经测定,相对效价分别为59.63%±4.57%,75.54%±4.05%,99.98%±9.63%,123.90%±5.54%和142.51%±12.82%;对应的回收率分别为93.17%±7.15%,94.42%±5.06%,99.98%±9.63%,99.12%±4.43%以及91.21%±8.21%,CV分别为7.67%,5.35%,9.63%,4.47%和9.00%,上述结果的变异系数CV值均<10%;实测效价与理论效价线性回归分析相关系数R^(2)=0.9823,线性良好;本研究建立的方法可以敏感检测出抗体结构变化对生物活性的影响,对双特异性抗体的稳定性检测有一定的指导意义。结论利用转基因细胞法成功建立了抗CD3/CD20双特异性抗体生物学活性检测方法,该方法专属性强、准确性高、重复性好,可用于评价抗CD3/CD20双特异性抗体生物学活性。

注射抗CD20单克隆抗体后发生荨麻疹性血管炎一例

患者,女,61岁。全身皮肤泛发红斑1天。起病前7天因“红斑型天疱疮”应用抗CD20单克隆抗体治疗。用药后躯干、四肢泛发水肿性红斑。结合组织病理诊断为荨麻疹性血管炎。给予甲泼尼龙、氯雷他定等治疗,4天后患者皮疹逐渐消退,原有红斑部位可见色素沉着斑。随访8个月,皮疹未复发。

原发纵隔CD20阴性弥漫大B细胞淋巴瘤1例并文献复习

回顾性分析1例原发纵隔CD20阴性弥漫大B细胞淋巴瘤病例的临床资料,并复习相关文献。患者,男,26岁反复胸痛3个月,影像学检查提示纵隔巨大占位,于外科行纵隔占位活检,术后免疫组织化学提示:CD20(-)、CD19(+)、PAX-5(+)、CD3(-)、CD5(-)、CD10(-)、TdT(-)、MUM1(+)、CD30(个别+)、Ki-67(约60%+)、BCL-2(+)、C-MYC(10%~20%)。诊断为CD20阴性弥漫大B细胞淋巴瘤,予以多疗程联合化疗后,疗效欠佳,病情进展,失访。CD20阴性弥漫大B细胞淋巴瘤侵袭性强,诊治难度大,预后差。